Trade Panbela Therapeutics, Inc. - PBLA CFD
Add to favourite- Summary
- Historical Data
Spread | 0.06 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
Prev. Close | 1.2 |
Open | 1.2 |
1-Year Change | 34.83% |
Day's Range | 1.07 - 1.24 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Mar 6, 2024 | 1.08 | -0.12 | -10.00% | 1.20 | 1.25 | 1.06 |
Mar 5, 2024 | 1.20 | 0.01 | 0.84% | 1.19 | 1.23 | 1.16 |
Mar 4, 2024 | 1.18 | -0.06 | -4.84% | 1.24 | 1.27 | 1.16 |
Mar 1, 2024 | 1.23 | 0.08 | 6.96% | 1.15 | 1.29 | 1.14 |
Feb 29, 2024 | 1.14 | -0.06 | -5.00% | 1.20 | 1.22 | 1.12 |
Feb 28, 2024 | 1.16 | -0.02 | -1.69% | 1.18 | 1.22 | 1.14 |
Feb 27, 2024 | 1.21 | 0.08 | 7.08% | 1.13 | 1.21 | 1.13 |
Feb 26, 2024 | 1.12 | 0.01 | 0.90% | 1.11 | 1.14 | 1.07 |
Feb 23, 2024 | 1.09 | 0.00 | 0.00% | 1.09 | 1.11 | 1.07 |
Feb 22, 2024 | 1.08 | -0.05 | -4.42% | 1.13 | 1.13 | 1.08 |
Feb 21, 2024 | 1.11 | -0.05 | -4.31% | 1.16 | 1.16 | 1.11 |
Feb 20, 2024 | 1.15 | -0.05 | -4.17% | 1.20 | 1.20 | 1.13 |
Feb 16, 2024 | 1.22 | -0.01 | -0.81% | 1.23 | 1.29 | 1.21 |
Feb 15, 2024 | 1.25 | -0.11 | -8.09% | 1.36 | 1.38 | 1.19 |
Feb 14, 2024 | 1.31 | 0.21 | 19.09% | 1.10 | 1.46 | 1.10 |
Feb 13, 2024 | 1.11 | -0.02 | -1.77% | 1.13 | 1.13 | 1.09 |
Feb 12, 2024 | 1.16 | -0.05 | -4.13% | 1.21 | 1.21 | 1.12 |
Feb 9, 2024 | 1.20 | 0.10 | 9.09% | 1.10 | 1.22 | 1.08 |
Feb 8, 2024 | 1.12 | -0.02 | -1.75% | 1.14 | 1.14 | 1.05 |
Feb 7, 2024 | 1.14 | 0.00 | 0.00% | 1.14 | 1.17 | 1.08 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Panbela Therapeutics, Inc. Company profile
About Panbela Therapeutics Inc
Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing disruptive therapeutics for the treatment of patients with cancer. The Company is engaged in the commercial development of a polyamine analogue for pancreatic cancer. Its product candidate includes SBP-101, which is a proprietary polyamine analogue that accumulates in the exocrine pancreas acinar cells due to its chemical structure. The Company is conducting Phase I a/I b study of the safety, efficacy and pharmacokinetics of SBP-101 administered in combination with two standard-of-care chemotherapy agents, gemcitabine and nab-paclitaxel.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Panbela Therapeutics Inc revenues was not reported. Net loss increased 70% to $6.6M. Higher net loss reflects Research and Development - Balancing increase of 90% to $3.2M (expense), General and administrative -Bal increase of 69% to $2.5M (expense), Other income decrease from $55K (income) to $611K (expense).
Industry: | Biotechnology & Medical Research (NEC) |
712 Vista Blvd # 305
55387
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com